Brokerages Anticipate Myokardia Inc (NASDAQ:MYOK) Will Announce Earnings of -$1.48 Per Share

Brokerages expect Myokardia Inc (NASDAQ:MYOK) to announce earnings of ($1.48) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Myokardia’s earnings. The highest EPS estimate is ($1.32) and the lowest is ($1.69). Myokardia reported earnings per share of ($1.34) in the same quarter last year, which would suggest a negative year over year growth rate of 10.4%. The company is scheduled to issue its next quarterly earnings results on Monday, November 2nd.

According to Zacks, analysts expect that Myokardia will report full year earnings of ($5.64) per share for the current fiscal year, with EPS estimates ranging from ($6.22) to ($5.09). For the next fiscal year, analysts anticipate that the firm will report earnings of ($5.99) per share, with EPS estimates ranging from ($7.02) to ($4.39). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Myokardia.

Myokardia (NASDAQ:MYOK) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.46) by $0.19.

MYOK has been the topic of a number of research reports. Cantor Fitzgerald increased their price target on Myokardia from $95.00 to $188.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. BidaskClub raised Myokardia from a “hold” rating to a “buy” rating in a research report on Wednesday, September 9th. Morgan Stanley boosted their price target on shares of Myokardia from $117.00 to $121.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. BMO Capital Markets reaffirmed a “buy” rating and issued a $148.00 price objective on shares of Myokardia in a report on Monday, August 31st. Finally, Credit Suisse Group reissued a “buy” rating and set a $136.00 target price on shares of Myokardia in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Myokardia has an average rating of “Buy” and an average target price of $127.70.

In other news, Director Mary B. Cranston sold 21,629 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $96.60, for a total value of $2,089,361.40. Following the completion of the transaction, the director now directly owns 371 shares in the company, valued at $35,838.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Anastasios Gianakakos sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $93.98, for a total transaction of $469,900.00. Following the transaction, the chief executive officer now owns 22,346 shares in the company, valued at approximately $2,100,077.08. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Myokardia by 13.4% in the second quarter. FMR LLC now owns 7,919,327 shares of the biotechnology company’s stock valued at $765,166,000 after buying an additional 933,147 shares during the period. Vanguard Group Inc. raised its position in Myokardia by 13.2% in the second quarter. Vanguard Group Inc. now owns 4,564,674 shares of the biotechnology company’s stock worth $441,039,000 after acquiring an additional 532,583 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Myokardia by 48.9% in the 1st quarter. Janus Henderson Group PLC now owns 1,524,881 shares of the biotechnology company’s stock valued at $71,486,000 after acquiring an additional 500,462 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Myokardia by 103.2% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 704,000 shares of the biotechnology company’s stock valued at $68,020,000 after purchasing an additional 357,591 shares in the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Myokardia in the 1st quarter worth approximately $15,640,000.

MYOK stock traded up $3.39 during midday trading on Wednesday, reaching $130.43. The company had a trading volume of 543,179 shares, compared to its average volume of 530,912. The firm has a market capitalization of $6.91 billion, a PE ratio of -18.34 and a beta of 2.20. The stock has a 50 day moving average price of $104.16 and a 200 day moving average price of $84.88. Myokardia has a fifty-two week low of $42.65 and a fifty-two week high of $133.98.

Myokardia Company Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

See Also: Why are trading ranges significant?

Get a free copy of the Zacks research report on Myokardia (MYOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.